Expanded Access to ABBV-787

AbbVie

Status

Conditions: Acute Myeloid Leukemia

Treatments: Drug: ABBV-787

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT06439966

C25-244

Details and patient eligibility

About

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-787 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• The participant must not be eligible for an ABBV-787 clinical trial.